

Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey [Corrigendum]

Innocenti R, Rigacci L, Restelli U, et al. *J Blood Med.* 2019;10:21–27.

On page 24, Figure 2, the key for the figure was incorrect. The corrected figure:




Figure 2 Kaplan–Meier plot of percentage of patients with bone marrow recovery at the time (days) of G-CSF discontinuation (lenograstim or filgrastim). **Abbreviation:** G-CSF, granulocyte-colony stimulating factor.

Publish your work in this journal

The Journal of Blood Medicine is an international, peer-reviewed, open access, online journal publishing laboratory, experimental and clinical aspects of all aspect pertaining to blood based medicine including but not limited to: Transfusion Medicine; Blood collection, Donor issues, Transmittable diseases, and Blood banking logistics; Immunohematology; Artificial and alternative

blood based therapeutics; Hematology; Biotechnology/nanotechnology of blood related medicine; Legal aspects of blood medicine; Historical perspectives. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/journal-of-blood-medicine-journal>